Cyclin E amplification/overexpression is a mechanism of trastuzumab resistance in HER2(+) breast cancer patients

Clinical benefits from trastuzumab and other anti-HER2 therapies in patients with HER2 amplified breast cancer remain limited by primary or acquired resistance. To identify potential mechanisms of resistance, we established trastuzumab-resistant HER2 amplified breast cancer cells by chronic exposure...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
Main Authors: Scaltriti, Maurizio, Eichhorn, Pieter J., Cortés, Javier, Prudkin, Ludmila, Aura, Claudia, Jiménez, José, Chandarlapaty, Sarat, Serra, Violeta, Prat, Aleix, Ibrahim, Yasir H., Guzmán, Marta, Gili, Magui, Rodríguez, Olga, Rodríguez, Sonia, Pérez, José, Green, Simon R., Mai, Sabine, Rosen, Neal, Hudis, Clifford, Baselga, José
פורמט: Artigo
שפה:Inglês
יצא לאור: National Academy of Sciences 2011
נושאים:
Biological Sciences
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC3048107/
https://ncbi.nlm.nih.gov/pubmed/21321214
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1073/pnas.1014835108
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים